## Permalink

# Screening Methods to Identify New Drugs for Atherosclerosis and Type II Diabetes

Tech ID: 22735 / UC Case 2005-149-0

# BACKGROUND

One class of drugs developed to treat diabetes is the thiazolidinediones, which include rosiglitazone (Avandia®), troglitazone (Rezulin®), and pioglitazone (ACTOS®). These insulin-sensitizing drugs have been shown to lower blood glucose levels in target tissues (muscle and fat) by modulating PPAR-g, a nuclear receptor involved in fat cell development and glucose homeostasis. Activators of PPAR-g have been shown to suppress the expression of inflammatory genes that play a role in impaired insulin signaling. However, thiazolidinediones have also been shown to exhibit serious side effects, including edema, anemia, and liver injury.

## **TECHNOLOGY DESCRIPTION**

Researchers from UC San Diego have patented a new method that identifies a novel molecular mechanism by which ligands regulate the transcriptional activities of nuclear receptors. This mechanism provides the basis for screening assays to identify novel ligands that repress inflammation by regulating nuclear receptor proteins like PPAR-g. Such compounds would potentially represent improvements over existing drugs used to treat type II diabetes which exhibit significant side effects.

#### **APPLICATIONS**

In 2012, 29.1 million Americans have diabetes (9.3% of population, up from 7% in 2002). In 2010, 79 million Americans age 20 and older had pre-diabetes. In 2012 this number grew to 86 million. According to the American Diabetes Association the total economic cost of diabetes back in 2002 was estimated at \$132 billion. In 2013 this total grew to \$245 billion.

### FEATURES/BENEFITS

- Potential increase in efficacy due to increased specificity
- Potential reduction in side effects

## STATE OF DEVELOPMENT

This patented technology is available for licensing in the US.

#### PATENT STATUS

Country	Туре	Number	Dated	Case
United States Of America	Issued Patent	8,241,863	08/14/2012	2005-149

University of California, San Diego Office of Innovation and Commercialization 9500 Gilman Drive, MC 0910, , La Jolla,CA 92093-0910

Tel: 858.534.5815 innovation@ucsd.edu https://innovation.ucsd.edu Fax: 858.534.7345

## CONTACT

University of California, San Diego Office of Innovation and Commercialization innovation@ucsd.edu tel: 858.534.5815.



#### INVENTORS

Glass, Christopher K.

## **OTHER INFORMATION**

KEYWORDS

diabetes, atherosclerosis,

inflammation, nuclear receptors,

insulin resistance, PPAR

#### **CATEGORIZED AS**

Medical

Disease: Cardiovascular

and Circulatory System

**RELATED CASES** 

2005-149-0

© 2012 - 2016, The Regents of the University of California Terms of use Privacy Notice